Assessment of clinical outcomes, long-term survival and toleration with sequential therapy of first-line Crizotinib followed by Alectinib in clinical practice for Chinese patients with advanced ALK positive Non-small-cell-lung-cancer
Latest Information Update: 12 Oct 2021
At a glance
- Drugs Alectinib (Primary) ; Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 12 Oct 2021 New trial record
- 14 Sep 2021 Results presented at the 2021 World Conference on Lung Cancer